BioForce Nanosciences Holdings, Inc.

As of June 30, 2026, BioForce Nanosciences Holdings, Inc. carries a market capitalization of 55.36M, placing it among publicly traded companies globally. Its enterprise value stands at 55.36M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, BioForce Nanosciences Holdings, Inc. has 33.55M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, BioForce Nanosciences Holdings, Inc. maintains a current ratio of 25.41, meaning it holds 25.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -8.23, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 3.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, BioForce Nanosciences Holdings, Inc.'s stock has gained approximately 918.91% over the past 52 weeks. The 50-day moving average sits at 6.84, while the 200-day moving average is 2.39.

Over the twelve months ended June 30, 2026, BioForce Nanosciences Holdings, Inc. generated - - in revenue and converted that into -98,249.00 in net income, yielding earnings per share of 0.00. EBITDA reached -613,776.00, while operating income came in at -613,776.00.

These figures are as of June 30, 2026. Total book value stands at 2.30M, with working capital of 2.07M providing operational flexibility.

BioForce Nanosciences Holdings, Inc. produced -41,934.00 in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.08: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.07, meaning BioForce Nanosciences Holdings, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

BioForce Nanosciences Holdings, Inc.'s most recent stock split took place on March 2, 2020 with a 5:1 split ratio.

As of June 30, 2026, BioForce Nanosciences Holdings, Inc. has an Altman Z-Score of 296.88, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.